ZERO WORLD RESEARCHアミノ酸・有機酸の学術文献データベース

Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD.

内皮型一酸化窒素経路の調節異常はCOPDにおける気道炎症と関連する (機械翻訳の邦題)

Respiratory research2019Csoma B, Bikov A, Nagy L, et al.
研究デザインその他の原著論文
対象ヒト

記録の確認項目

研究デザイン
その他の原著論文
対象
ヒト
出版年
2019
出典
doi.org
抄録の表示
表示あり
出版状態
有効な記録
状態確認日
2026/08/17
収集日
2026/08/03
鮮度
確認期限内
確認段階
自動処理
記録状態
公開

日本語要約(機械生成)

慢性閉塞性肺疾患(COPD)では内皮機能障害と一酸化窒素(NO)産生低下が知られるが、内皮型NO合成酵素(eNOS)機能障害と気道炎症の関連は不明である。本研究は、対照喫煙者15名、安定型COPD患者29名、増悪型COPD患者32名(うち20名は入院時と退院時を測定)を対象に、血清ADMA、SDMA、亜硝酸塩/硝酸塩濃度を測定し、気道炎症マーカー(呼気NO濃度、喀痰中炎症細胞数など)との相関を検討した。結果、安定型・増悪型COPDでL-アルギニン/ADMA比が低下し、増悪時にはSDMAが上昇した。ADMAは血中好中球比率および呼気NOと正相関し、SDMAは喀痰中総炎症細胞数および好中球数と正相関した。増悪時のステロイド治療後、SDMAは低下した。血清亜硝酸塩は安定型・増悪型で増加した。これらの結果から、COPDではeNOS機能障害が存在し、増悪時に一過性に悪化、ステロイド治療で部分的に改善すること、ADMAとSDMAが気道炎症マーカーと相関することが示唆された。

この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。

抄録

Background: Chronic obstructive pulmonary disease (COPD) is related to endothelial dysfunction and the impaired generation of nitric oxide (NO) from L-arginine by the endothelial NO synthase (eNOS). The relationship between eNOS dysfunctionality and airway inflammation is unknown. We assessed serum asymmetric and symmetric dimethylarginine (ADMA and SDMA) and nitrite/nitrate concentrations, indicators of eNOS function, in patients with COPD and correlated them with markers of inflammation.Methods: We recruited 15 control smokers, 29 patients with stable and 32 patients with exacerbated COPD requiring hospitalization (20 of them were measured both at admission and discharge). Serum L-arginine, ADMA, SDMA, nitrite and nitrate were measured and correlated with airway inflammatory markers (fractional exhaled nitric oxide concentration - FENO, sputum nitrite and nitrate, sputum cellularity), serum C-reactive protein - CRP, white blood cell count, lung function and blood gases. ANOVA, t-tests and Pearson correlation were used (mean ± SD or geometric mean ± geometric SD for nitrite/nitrate).Results: Serum L-arginine/ADMA, a marker of substrate availability for eNOS, was lower in stable (214 ± 58, p < 0.01) and exacerbated COPD (231 ± 68, p < 0.05) than in controls (287 ± 64). The serum concentration of SDMA, a competitor of L-arginine transport, was elevated during an exacerbation (0.78 ± 0.39 μM) compared to stable patients (0.53 ± 0.14 μM, p < 0.01) and controls (0.45 ± 0.14 μM, p < 0.001). ADMA correlated with blood neutrophil percentage (r = 0.36, p < 0.01), FENO (r = 0.42, p < 0.01) and a tendency for positive association was observed to sputum neutrophil count (r = 0.33, p = 0.07). SDMA correlated with total sputum inflammatory cell count (r = 0.61, p < 0.01) and sputum neutrophil count (r = 0.62, p < 0.01). Markers were not related to lung function, blood gases or CRP. L-arginine/ADMA was unchanged, but serum SDMA level decreased (0.57 ± 0.42 μM, p < 0.05) after systemic steroid treatment of the exacerbation. Serum nitrite level increased in stable and exacerbated disease (4.11 ± 2.12 and 4.03 ± 1.77 vs. control: 1.61 ± 1.84 μM, both p < 0.001).Conclusions: Our data suggest impaired eNOS function in stable COPD, which is transiently aggravated during an exacerbation and partly reversed by systemic steroid treatment. Serum ADMA and SDMA correlate with airway inflammatory markers implying a possible effect of anti-inflammatory therapy on endothelial dysfunction. Serum nitrite can serve as a compensatory pool for impaired endothelial NO generation.

MeSH

AgedBiomarkersFemaleHumansInflammation MediatorsMaleMiddle AgedNitric Oxide Synthase Type IIIPulmonary Disease, Chronic ObstructiveSignal TransductionSputum

DOI 10.1186/s12931-019-1133-8

PMID 31311549

原文・出典を見る →